GEHC (GE HealthCare Technologies) 5-Year EBITDA Growth Rate: 1.90% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GEHC GE HealthCare Technologies Inc GEHC
72 GF Score
Price $73.69
GF Value $84.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is GE HealthCare Technologies 5-Year EBITDA Growth Rate?

GE HealthCare Technologies GEHC -0.15% 72 5-Year EBITDA Growth Rate is 1.90% as of Jun. 2026. GuruFocus rates GEHC with a GF Score™ of 72/100 and a GF Value™ of $84.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

GE HealthCare Technologies's EBITDA per Share for the three months ended in Jun. 2026 was $2.13.

During the past 12 months, GE HealthCare Technologies's average EBITDA Per Share Growth Rate was -3.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 5.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of GE HealthCare Technologies was 5.10% per year. The lowest was 0.80% per year. And the median was 2.70% per year.


GE HealthCare Technologies  (NAS:GEHC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


GE HealthCare Technologies 5-Year EBITDA Growth Rate Related Terms


GEHC vs DXCM, STE, ZBH: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, GE HealthCare Technologies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GE HealthCare Technologies 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where GE HealthCare Technologies's 5-Year EBITDA Growth Rate falls into.


GEHC
72GF Score
GE HealthCare Technologies Inc GEHC
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GE HealthCare Technologies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 1.90% mean?
GE HealthCare Technologies (GEHC) has a 5-Year EBITDA Growth Rate of 1.90% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for GE HealthCare Technologies and its competitors.
Is GE HealthCare Technologies' 5-Year EBITDA Growth Rate too high?
GE HealthCare Technologies' current 5-Year EBITDA Growth Rate is 1.90%. Overall, GE HealthCare Technologies has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' 5-Year EBITDA Growth Rate compare to DXCM and STE?
GE HealthCare Technologies' 5-Year EBITDA Growth Rate of 1.90% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for GE HealthCare Technologies and its competitors. GE HealthCare Technologies's current 5-Year EBITDA Growth Rate is 1.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (GEHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $84.16, compared to a current price of $73.69 — trading 12.4% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 1.90%. GE HealthCare Technologies' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For GE HealthCare Technologies (GEHC), the current 5-Year EBITDA Growth Rate is 1.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GE HealthCare Technologies (GEHC) Overvalued in 2026?

Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued. The current stock price of $73.69 is trading 12.4% below its estimated GF Value™ of $84.16. GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.

Key valuation signals for GEHC:

  • 5-Year EBITDA Growth Rate: 1.90%
  • GF Value™: $84.16 vs. price of $73.69 (12.4% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the GEHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GE HealthCare Technologies Business Description

Address 500 West Monroe Street, Chicago, IL, USA, 60661
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
72GF Score

Get the complete analysis for GEHC

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$73.69
Price
$84.16
GF Value